Abstract
Treatment of osteosarcoma requires a combined approach of surgery of the primary tumor and systemic chemotherapy.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Bibliography
Anninga JK, Gelderblom H, Fiocco M, Kroep JR, Taminiau AH, Hogendoorn PC, Egeler RM (2011) Chemotherapeutic adjuvant treatment for osteosarcoma: where do we stand? Eur J Cancer 47(16):2431–2445
Bacci G, Ferrari S, Bertoni F et al (2000) Long-term outcome for patients with nonmetastatic osteosarcoma of the extremity treated at the istituto ortopedico rizzoli according to the istituto ortopedico rizzoli/osteosarcoma-2 protocol: an updated report. J Clin Oncol 18:4016–4027
Bacci G, Briccoli A, Rocca M et al (2003) Neoadjuvant chemotherapy for osteosarcoma of the extremities with metastases at presentation: recent experience at the Rizzoli Institute in 57 patients treated with cisplatin, doxorubicin, and a high dose of methotrexate and ifosfamide. Ann Oncol 14(7):1126–1134
Bacci G, Longhi A, Versari M et al (2006) Prognostic factors for osteosarcoma of the extremity treated with neoadjuvant chemotherapy: 15-year experience in 789 patients treated at a single institution. Cancer 106:1154–1161
Bielack SS, Smeland S, Whelan J et al (2013) MAP plus maintenance pegylated interferon α-2b (MAPIfn) versus MAP alone in patients with resectable high-grade osteosarcoma and good histologic response to preoperative MAP: first results of the EURAMOS-1 “good response” randomization. J Clin Oncol 31 (suppl; abstr LBA10504)
Campanacci M (1999) High grade osteosarcomas. In: Campanacci M (ed) Bone and soft tissue tumors, 2nd edn. Springer, Wien/New York, pp 463–515
Chou AJ, Merola PR, Wexler LH et al (2005) Treatment of osteosarcoma at first recurrence after contemporary therapy: the Memorial Sloan-Kettering Cancer Center experience. Cancer 104:2214–2221
Chou AJ, Kleinerman ES, Krailo M et al (2009) Addition of muramyl tripeptide to chemotherapy for patients with newly diagnosed metastatic osteosarcoma: a report from the Children’s Oncology Group. Cancer 115(22):5339–5348
Crompton BD, Re G, Weinberg VK et al (2006) Survival after recurrence of osteosarcoma: a 20-year experience at a single institution. Pediatr Blood Cancer 47:255–259
Daw NC, Billups CA, Rodriguez-Galindo C et al (2006) Metastatic osteosarcoma. Cancer 106:403–412
Denecke T, Hundsdörfer P, Misch D et al (2010) Assessment of histological response of paediatric bone sarcomas using FDG PET in comparison to morphological volume measurement and standardized MRI parameters. Eur J Nucl Med Mol Imaging 37(10):1842–1853
Ferrari S, Briccoli A, Mercuri M et al (2003) Postrelapse survival in osteosarcoma of the extremities: prognostic factors for long-term survival. J Clin Oncol 21(4):710–715
Ferrari S, Smeland S, Mercuri M et al (2005) Neoadjuvant chemotherapy with high-dose ifosfamide, high-dose methotrexate, cisplatin, and doxorubicin for patients with localized osteosarcoma of the extremity: a joint study by the Italian and Scandinavian Sarcoma Groups. J Clin Oncol 23:8845–8852
Ferrari S, Ruggieri P, Cefalo G et al (2012) Neoadjuvant chemotherapy with methotrexate, cisplatin, and doxorubicin with or without ifosfamide in nonmetastatic osteosarcoma of the extremity: an Italian sarcoma group trial ISG/OS-1. J Clin Oncol 30(17):2112–2118
Fuchs N, Bielack SS, Epler D et al (1998) Long-term results of the co-operative German-Austrian-Swiss osteosarcoma study group's protocol COSS-86 of intensive multidrug chemotherapy and surgery for osteosarcoma of the limbs. Ann Oncol 9:893–899
Grignani G, Palmerini E, Dileo P et al (2012) A phase II trial of sorafenib in relapsed and unresectable high-grade osteosarcoma after failure of standard multimodal therapy: an Italian Sarcoma Group study. Ann Oncol 23(2):508–516
Kong CB, Byun BH, Lim I et al (2013)18F-FDG PET SUVmax as an indicator of histopathologic response after neoadjuvant chemotherapy in extremity osteosarcoma. Eur J Nucl Med Mol Imaging 40(5):728–736
Man TK, Chintagumpala M, Visvanathan J et al (2005) Expression profiles of osteosarcoma that can predict response to chemotherapy. Cancer Res 65:8142–8150
Meyers PA, Schwartz CL, Krailo M et al (2005) Osteosarcoma: a randomized, prospective trial of the addition of ifosfamide and/or muramyl tripeptide to cisplatin, doxorubicin, and high-dose methotrexate. J Clin Oncol 23:2004–2011
Rosen G, Caparros B, Huvos A et al (1982) Preoperative chemotherapy for osteogenic sarcoma: Selection of postoperative adjuvant chemotherapy based on the response of the primary tumor to preoperative chemotherapy. Cancer 49:1221–1230
Whelan JS, Jinks RC, McTiernan A et al (2012) Survival from high-grade localised extremity osteosarcoma: combined results and prognostic factors from three European Osteosarcoma Intergroup randomised controlled trials. Ann Oncol 23(6):1607–1616
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2014 Springer International Publishing Switzerland
About this chapter
Cite this chapter
Ferrari, S. (2014). Chemotherapy in Osteosarcoma. In: Picci, P., Manfrini, M., Fabbri, N., Gambarotti, M., Vanel, D. (eds) Atlas of Musculoskeletal Tumors and Tumorlike Lesions. Springer, Cham. https://doi.org/10.1007/978-3-319-01748-8_44
Download citation
DOI: https://doi.org/10.1007/978-3-319-01748-8_44
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-01747-1
Online ISBN: 978-3-319-01748-8
eBook Packages: MedicineMedicine (R0)